

**NEWS RELEASE – FOR IMMEDIATE RELEASE**  
**23rd May 2001**

**-COPY STARTS -**

**CAMBRIDGE DRUG DISCOVERY LIMITED PARTNERS ANTI-INFLAMMATORY  
DISCOVERY PROGRAMME WITH TEIJIN LIMITED TO DISCOVER NOVEL DRUG  
CANDIDATES**

Cambridge Drug Discovery Limited (Cambridge Drug Discovery) and Teijin Limited (Teijin), today announced that they have entered into a key collaborative agreement focused towards the identification of novel lead compounds for the treatment of inflammatory disorders. The collaboration is based on a discovery programme already underway at Cambridge Drug Discovery and the new alliance follows on from the completion of a research project earlier this year. The current agreement represents the second alliance between Cambridge Drug Discovery and Teijin. Financial details were not disclosed

In the first phase of the programme, Teijin will have access to Cambridge Drug Discovery's target and assay development technologies as well as the Company's fully automated high-throughput screening system and diverse compound library of "drug-like" molecules. The collaboration will initially be focused on the identification of lead candidates with an option to expand the collaboration leading to the discovery of clinical drug candidates with CDD providing lead optimisation, chemistry and biology support.

Commenting on this new collaboration, Cambridge Drug Discovery's Chief Executive Officer, Dr Mark Treherne said "We are extremely pleased to build on our rewarding relationship and look forward to partnering this programme with Teijin and continuing our successful working partnership. We are confident of identifying novel drugs for rapid pre-clinical development."

Dr Atsushi Imaizumi, Director of Pharmaceutical Discovery Research Laboratories of Teijin, commented that, "We are very happy to start a new collaboration programme with CDD. Teijin and CDD will work very closely together to obtain drug-like lead molecules. This is the second Teijin/CDD project and we knew each other very well, therefore, we are expecting not only the quality of the molecules but also the speed of discovery."

**-ENDS -**

**For further information, please contact:**

**Cambridge Drug Discovery Limited**

Dr. Mark Treherne, Chief Executive Officer, Cambridge Drug Discovery Ltd, Cambridge Science Park, Milton Road, Cambridge, CB4 0FG, UK.

Tel: +44 (0) 1223 723 222  
E-mail: [info@camdd.co.uk](mailto:info@camdd.co.uk)

Fax: +44 (0) 1223 723 223  
Web site: [www.camdd.co.uk](http://www.camdd.co.uk)

**Teijin Limited**

Dr. Yoshihiko Sumi Senior Manager, Pharmaceutical Planning Department, Teijin Limited  
2-1-1 Uchisaiwai-cho, Chiyoda-ku, Tokyo 100-8585, Japan

Tel: +81 (0)3 3506 4107

Fax: +81 (0)3 3506 4498

E-mail: [y.sumi@teijin.co.jp](mailto:y.sumi@teijin.co.jp)

Web site: [www.teijin.co.jp](http://www.teijin.co.jp)

**Noonan Russo Limited**

Don O'Sullivan, Noonan Russo Ltd, 15 Basinghall Street, London, EC2V 5BR

Tel: +44 (0) 207 726 4452

Fax: +44 (0) 207 726 4453

Email: [DO'Sullivan@noonan.russo.co.uk](mailto:DO'Sullivan@noonan.russo.co.uk)

Web site : <http://www.noonanrusson.com>

**Note to Editors**

**About Cambridge Drug Discovery**

Cambridge Drug Discovery Ltd provides a range of biological technologies, expertise and resources to accelerate the drug discovery process. The Company's platform strength stems from its target discovery, assay development, efficient high-throughput screening and integrated informatics capabilities that Cambridge Drug Discovery exploits to enhance its partners' drug discovery programmes. The company is based in Cambridge, UK, and was set up in 1997. Cambridge Drug Discovery is the trading entity of Cambridge Drug Discovery Holdings Ltd.

**About Teijin Limited**

The Company's operations encompass five segments: Fibres & Textiles; Films & Plastics; Pharmaceuticals & Home Health Care; Machinery & Engineering; New Products & Other B businesses. Teijin Limited's Pharmaceuticals & Home Health Care operations date back nearly 30 years. Since then, the Company has pursued independent research as well as co-operative efforts with leading organisations in Japan and abroad to strengthen its specialised capabilities. The Company has developed and brought to market more than 10 innovative pharmaceuticals in three therapeutic areas: cardiovascular disorders, respiratory ailments and bone calcium metabolism disorders.